Home / Health / Transplant Breakthrough: Ditch Anti-Rejection Drugs?
Transplant Breakthrough: Ditch Anti-Rejection Drugs?
17 Apr
Summary
- Researchers trained immune systems to accept new livers.
- Three patients stopped anti-rejection drugs for years.
- This may offer a new, less toxic transplant approach.
A pioneering study from the University of Pittsburgh has demonstrated a potential new method for organ transplantation, aiming to eliminate the need for anti-rejection drugs. Researchers have begun training recipients' immune systems to accept transplanted organs by introducing specific immune cells from the donor. This approach, detailed in Nature Communications, has shown promising results in a small group of liver transplant patients.
Three out of eight patients in the study have successfully discontinued immunosuppressive medications for at least three years. This achievement marks a significant step towards a long-sought goal in transplantation: inducing immune tolerance. The conventional anti-rejection drugs, while critical for preventing organ rejection, carry substantial risks including increased susceptibility to infections, cancer, and metabolic disorders.
The research team focused on liver transplants, a procedure where a degree of natural tolerance is already observed. They utilized dendritic cells, a type of immune cell that helps the body differentiate self from non-self, from organ donors. Administering these cells before or shortly after transplantation is theorized to 'prime' the recipient's immune system to accept the new organ without aggressive suppression.
One participant, Barbara Bowser, has lived without anti-rejection drugs for six and a half years following her liver transplant in January 2018. She reported feeling like her old self, a stark contrast to the debilitating side effects of the medications she experienced for nine months post-surgery. This success offers a beacon of hope for future transplant recipients.
